ProQR Therapeutics NV (PRQR) Sees Significant Increase in Short Interest

ProQR Therapeutics NV (NASDAQ:PRQR) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 985,408 shares, an increase of 60.6% from the October 15th total of 613,551 shares. Currently, 3.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 254,800 shares, the days-to-cover ratio is currently 3.9 days.

Shares of PRQR stock opened at $19.08 on Friday. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $817.59 million, a P/E ratio of -9.84 and a beta of 0.54. ProQR Therapeutics has a one year low of $2.75 and a one year high of $24.00.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.10. Research analysts expect that ProQR Therapeutics will post -1.38 earnings per share for the current fiscal year.

Several analysts recently commented on PRQR shares. Zacks Investment Research raised ProQR Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Thursday, August 9th. HC Wainwright set a $20.00 price target on ProQR Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 9th. Chardan Capital reaffirmed a “buy” rating and issued a $9.00 price target on shares of ProQR Therapeutics in a research note on Monday, August 13th. ValuEngine lowered ProQR Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 30th. Finally, Evercore ISI started coverage on ProQR Therapeutics in a research note on Tuesday, September 18th. They issued an “outperform” rating and a $35.00 price target on the stock. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. ProQR Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $18.00.

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. raised its position in ProQR Therapeutics by 519.0% in the 1st quarter. JPMorgan Chase & Co. now owns 33,425 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 28,025 shares during the last quarter. Millennium Management LLC bought a new position in ProQR Therapeutics in the 2nd quarter valued at $1,426,000. Ardsley Advisory Partners bought a new position in ProQR Therapeutics in the 2nd quarter valued at $365,000. Jennison Associates LLC raised its position in ProQR Therapeutics by 1.0% in the 2nd quarter. Jennison Associates LLC now owns 2,981,205 shares of the biopharmaceutical company’s stock valued at $21,763,000 after purchasing an additional 30,831 shares during the last quarter. Finally, Franklin Street Advisors Inc. NC raised its position in ProQR Therapeutics by 50.0% in the 2nd quarter. Franklin Street Advisors Inc. NC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $657,000 after purchasing an additional 30,000 shares during the last quarter. Hedge funds and other institutional investors own 28.55% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “ProQR Therapeutics NV (PRQR) Sees Significant Increase in Short Interest” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2018/11/10/proqr-therapeutics-nv-prqr-sees-significant-increase-in-short-interest.html.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Read More: Dividend Aristocrat Index

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply